Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2017-09, Vol.28, p.v82-v82 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | v82 |
|---|---|
| container_issue | |
| container_start_page | v82 |
| container_title | Annals of oncology |
| container_volume | 28 |
| creator | Beeram, M. Hamilton, E. Blum Murphy, M. Hausman, D. Infante, J.R. Korn, R. Patnaik, A. Piha-Paul, S.A. Rasco, D. Rowse, G. Thimmarayappa, J. Tolcher, A. Meric-Bernstam, F. |
| description | |
| doi_str_mv | 10.1093/annonc/mdx365.018 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx365_018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753420376791</els_id><sourcerecordid>S0923753420376791</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1858-44f42ca5ba128ffe0b9c747543886039c73f2ffa740a17dafdf52c3dbae6a1753</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoWKs_wFuOCt2abDb7gSeRaoWCIorgZZlNJm2kzS5J1PYX-Lfdsp49De_A8zLzEHLO2ZSzSlyBc61TVxu9FbmcMl4ekBGXeZWULOOHZMSqVCSFFNkxOQnhgzGWV2k1Ij9PKwhIOdVtwASDgjVE2zoa4qfe0dbQYN1yjQks0UX6_pbKCQU6nz2nSQS_xIiaNjZ0qKyxioKLtmn1bkKto11f1VOBXnQxXNJvG1cDidvOY9g3UwVOoQ-n5MjAOuDZ3xyT17vZy-08WTzeP9zeLBLFS1kmWWayVIFsgKelMciaShVZITNRljkTfRAmNQaKjAEvNBhtZKqEbgDzfiHFmPChV_k2BI-m7rzdgN_VnNV7k_Vgsh5M1r3JnrkeGOwP-7Lo66D6vxRq61HFWrf2H_oX9ut_aA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Beeram, M. ; Hamilton, E. ; Blum Murphy, M. ; Hausman, D. ; Infante, J.R. ; Korn, R. ; Patnaik, A. ; Piha-Paul, S.A. ; Rasco, D. ; Rowse, G. ; Thimmarayappa, J. ; Tolcher, A. ; Meric-Bernstam, F.</creator><creatorcontrib>Beeram, M. ; Hamilton, E. ; Blum Murphy, M. ; Hausman, D. ; Infante, J.R. ; Korn, R. ; Patnaik, A. ; Piha-Paul, S.A. ; Rasco, D. ; Rowse, G. ; Thimmarayappa, J. ; Tolcher, A. ; Meric-Bernstam, F.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx365.018</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2017-09, Vol.28, p.v82-v82</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1858-44f42ca5ba128ffe0b9c747543886039c73f2ffa740a17dafdf52c3dbae6a1753</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Beeram, M.</creatorcontrib><creatorcontrib>Hamilton, E.</creatorcontrib><creatorcontrib>Blum Murphy, M.</creatorcontrib><creatorcontrib>Hausman, D.</creatorcontrib><creatorcontrib>Infante, J.R.</creatorcontrib><creatorcontrib>Korn, R.</creatorcontrib><creatorcontrib>Patnaik, A.</creatorcontrib><creatorcontrib>Piha-Paul, S.A.</creatorcontrib><creatorcontrib>Rasco, D.</creatorcontrib><creatorcontrib>Rowse, G.</creatorcontrib><creatorcontrib>Thimmarayappa, J.</creatorcontrib><creatorcontrib>Tolcher, A.</creatorcontrib><creatorcontrib>Meric-Bernstam, F.</creatorcontrib><title>Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMoWKs_wFuOCt2abDb7gSeRaoWCIorgZZlNJm2kzS5J1PYX-Lfdsp49De_A8zLzEHLO2ZSzSlyBc61TVxu9FbmcMl4ekBGXeZWULOOHZMSqVCSFFNkxOQnhgzGWV2k1Ij9PKwhIOdVtwASDgjVE2zoa4qfe0dbQYN1yjQks0UX6_pbKCQU6nz2nSQS_xIiaNjZ0qKyxioKLtmn1bkKto11f1VOBXnQxXNJvG1cDidvOY9g3UwVOoQ-n5MjAOuDZ3xyT17vZy-08WTzeP9zeLBLFS1kmWWayVIFsgKelMciaShVZITNRljkTfRAmNQaKjAEvNBhtZKqEbgDzfiHFmPChV_k2BI-m7rzdgN_VnNV7k_Vgsh5M1r3JnrkeGOwP-7Lo66D6vxRq61HFWrf2H_oX9ut_aA</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Beeram, M.</creator><creator>Hamilton, E.</creator><creator>Blum Murphy, M.</creator><creator>Hausman, D.</creator><creator>Infante, J.R.</creator><creator>Korn, R.</creator><creator>Patnaik, A.</creator><creator>Piha-Paul, S.A.</creator><creator>Rasco, D.</creator><creator>Rowse, G.</creator><creator>Thimmarayappa, J.</creator><creator>Tolcher, A.</creator><creator>Meric-Bernstam, F.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201709</creationdate><title>Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers</title><author>Beeram, M. ; Hamilton, E. ; Blum Murphy, M. ; Hausman, D. ; Infante, J.R. ; Korn, R. ; Patnaik, A. ; Piha-Paul, S.A. ; Rasco, D. ; Rowse, G. ; Thimmarayappa, J. ; Tolcher, A. ; Meric-Bernstam, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1858-44f42ca5ba128ffe0b9c747543886039c73f2ffa740a17dafdf52c3dbae6a1753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beeram, M.</creatorcontrib><creatorcontrib>Hamilton, E.</creatorcontrib><creatorcontrib>Blum Murphy, M.</creatorcontrib><creatorcontrib>Hausman, D.</creatorcontrib><creatorcontrib>Infante, J.R.</creatorcontrib><creatorcontrib>Korn, R.</creatorcontrib><creatorcontrib>Patnaik, A.</creatorcontrib><creatorcontrib>Piha-Paul, S.A.</creatorcontrib><creatorcontrib>Rasco, D.</creatorcontrib><creatorcontrib>Rowse, G.</creatorcontrib><creatorcontrib>Thimmarayappa, J.</creatorcontrib><creatorcontrib>Tolcher, A.</creatorcontrib><creatorcontrib>Meric-Bernstam, F.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beeram, M.</au><au>Hamilton, E.</au><au>Blum Murphy, M.</au><au>Hausman, D.</au><au>Infante, J.R.</au><au>Korn, R.</au><au>Patnaik, A.</au><au>Piha-Paul, S.A.</au><au>Rasco, D.</au><au>Rowse, G.</au><au>Thimmarayappa, J.</au><au>Tolcher, A.</au><au>Meric-Bernstam, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers</atitle><jtitle>Annals of oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>28</volume><spage>v82</spage><epage>v82</epage><pages>v82-v82</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdx365.018</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2017-09, Vol.28, p.v82-v82 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdx365_018 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T01%3A00%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%201%20dose-escalation%20study%20of%20single-agent%20ZW25,%20a%20HER2-targeted%20bispecific%20antibody,%20in%20patients%20(pts)%20with%20HER2-expressing%20cancers&rft.jtitle=Annals%20of%20oncology&rft.au=Beeram,%20M.&rft.date=2017-09&rft.volume=28&rft.spage=v82&rft.epage=v82&rft.pages=v82-v82&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx365.018&rft_dat=%3Celsevier_cross%3ES0923753420376791%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753420376791&rfr_iscdi=true |